Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2022 on Thursday, April 28, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To listen, call 844-200-6205 within the U.S. or 929-526-1599 outside the U.S., access code: 49326

Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022

Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.

Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake

Bio-Rad Laboratories provides a range of products for the life science and clinical diagnostics markets.

Bio-Rad Laboratories: Cutting Edge Tech And Financial Success

Bio-Rad (BIO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Bio-Rad (BIO) Loses 15.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its underwritten public offering of $1.2 billion aggregate principal amount of the following notes (the “Notes”), each issued at par: $400 million aggregate principal amount due 2027 and $800 million aggregate principal amount due 2032. The five year Notes bear interest at an annual rate of 3.300% and the te

Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST today in New York City. During the event, members of Bio-Rad's executive leadership team will provide an in-depth overview of the Company's growth strategy and new long-term financial targets, as well a closer look at the drivers within the two core business segments – Life

Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day

Apple

Deere & Company

Amplify Mobile Payments ETF

JPMorgan Chase & Co

SmartETFs Advertising & Marketing Technology ETF

Invesco S&P 500 Equal Weight Technology ETF

The recent market rout offers an opportune entry point to these seven robust stocks. These are good stocks to buy at their bottom now.

7 Stocks To Buy at the Bottom After the Market Rout

Incyte

First Solar

For the past half dozen years, investors couldn't care less about a company's balance sheet.

All Hail the Balance Sheet Powerhouses

The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Bio-Rad (BIO) Could Surge 42%: Read This Before Placing a Bet

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down

Bio Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q4 2021 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q4 Earnings Top Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and year ended December 31, 2021. Fourth-quarter 2021 net sales were $732.8 million, a decrease of 7.2 percent compared to $789.8 million reported for the fourth quarter of 2020. On a currency-neutral basis, quarterly sales decreased 6.9 percent compared to the same period in 2020.

Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today that it will host an in-person investor day in New York City on Friday, February 25, 2022, at 10:30 a.m. EST. A live webcast will also be available. Registration is required to attend the event. The event will feature presentations from Norman Schwartz, Chief Executive Officer, and other key members of Bio-Rad's executive

Bio-Rad to Host Investor Day on February 25

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2021 on Thursday, February 10, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To listen, call 844-200-6205 within the U.S. or 929-526-1599 outside the U.S.,

Bio-Rad to Report Fourth-Quarter and Full-Year 2021 Financial Results, Thursday, February 10, 2022

Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.

Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate in a virtual Fireside Chat during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 PM (PST). A link to the live webcast is available in

Bio-Rad to Participate in Fireside Chat During the 40th Annual J.P. Morgan Healthcare Conference on January 11

Agios Pharmaceuticals

Enova Int.

Genworth Financial

SAGE Therapeutics

Shenandoah Telecommunications

Smith & Wesson Brands

eBay

Ironwood Pharma

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?

Robot Portfolio: Value in the Extreme

Bio-Rad Laboratories continues to report impressive earnings and has been on a winning streak with nearly two years of strong beats on EPS and revenue. The company's expansive product portfolio has facilitated growth during the pandemic. Now, both the Life Sciences and Clinical Diagnostics segments are showing sequential growth.

Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Has Bio-Rad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Simon May as Executive Vice President and President of the Life Science Group, effective January 4, 2022. He succeeds Annette Tumolo who will retire from this role at that time. Dr. May will be responsible for providing leadership and management of the overall strategy and business direction for the comp

Bio-Rad Appoints Simon May Executive Vice President and Life Science Group President

Business First Bancshares Inc.

B. Riley Financial

Commercial Metals

CTO Realty Growth

Gray TV

Northeast Bancorp

PennyMac Financial Services

SmartFinancial

The Bunny Portfolio is hopping again. It bounced to a 36.6% return in the past year.

News for Bio-Rad Laboratories Stock (BIO)